HLA
OLMA icon

Hamilton Lane Advisors’s Olema Pharmaceuticals OLMA Stock Holding History

Hamilton Lane Advisors’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-12,114
Closed -$402K – 85
2021
Q1 		$402K Buy
+12,114
New +$519K 0.13% 58

Other funds holding OLMA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Hamilton Lane Advisors's OLMA Position: Q2 2021 in Review

Hamilton Lane Advisors sold out of Olema Pharmaceuticals (OLMA) in Q2 2021, closing a stake of 12,114 shares — an estimated $402K sold.

Hamilton Lane Advisors first reported a position in OLMA in Q1 2021 and held it in 1 quarter. The position peaked at $402K in Q1 2021. 69 funds tracked by Wall St. Rank hold OLMA as of Q2 2021.

  • Hamilton Lane Advisors reported no remaining Olema Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Hamilton Lane Advisors sold 12,114 Olema Pharmaceuticals shares in Q2 2021, an estimated $402K.
  • Hamilton Lane Advisors first reported a position in Olema Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Hamilton Lane Advisors's Olema Pharmaceuticals position peaked at $402K in Q1 2021.
  • 69 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2021.

Based on Hamilton Lane Advisors's 13F filing for Q2 2021, filed 20 Jul 2021.